IND-enabling development of RX100 as a medical countermeasure for gastrointestinal acute radiation syndrome.

Ended Definitive Contract Awarded Sep 1, 2018 Last action Dec 6, 2022

Contract number: 75N93018C00052
Awardee: Rxbio, Inc. UEI DB9LSMAHKNJ8
Awarding agency: National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
Obligated: $4,591,512

Award facts

Opportunity: HHSNIHNIAIDBAA20171 Solicitation number
Contract value 100% obligated: $4,591,511.92 Current and potential, with all options
Completion date 100% complete: Oct 31, 2022 Current and potential, with all options
NAICS code: 541713 Research and Development in Nanotechnology
PSC: AN13 Health R&D Services; Health Care Services; Experimental Development
Set-aside: No set-aside
Competition: Full and Open Competition · 12 offers Negotiated Proposal / Quote
Pricing: Cost Plus Fixed Fee
Place of performance: Memphis, TN 37501, USA
Legislative mandates: Employment Eligibility Verification (E-Verify) FAR subpart 22.18

Service Contract Inventory FAR subpart 4.17

Award details come from SAM.gov/FPDS.

Transactions

Action	Obligated	Date
Other Administrative Action P00021	$0	Dec 6, 2022
Other Administrative Action P00020	$0	Jun 22, 2022
Funding Only Action P00019	$18,430	May 26, 2022
Other Administrative Action P00018	$0	Apr 5, 2022
Other Administrative Action P00017	$0	Jan 14, 2022
Other Administrative Action P00016	$0	Nov 30, 2021
Other Administrative Action P00015	$0	Sep 14, 2021
Other Administrative Action P00014	$0	Aug 6, 2021
Other Administrative Action P00013	$0	Jan 12, 2021
Other Administrative Action P00012	$0	Nov 20, 2020
Other Administrative Action P00011	$0	Nov 3, 2020
Other Administrative Action P00010	$0	Sep 9, 2020
Exercise an Option P00009	$1,524,658	Aug 17, 2020
Other Administrative Action P00008	$0	Jul 14, 2020
Other Administrative Action P00007	$0	Feb 24, 2020
Other Administrative Action P00006	$0	Jan 23, 2020
Other Administrative Action P00005 · To revise article B.3. Advance understandings, paragraph B., subcontract.	$0	Sep 27, 2019
Other Administrative Action P00004 · To extend the end date of the base period of the contract to february 28, 2020 without adding additional funds.	$0	Aug 30, 2019
Exercise an Option P00003 · To exercise option 1, 9/1/2019-8/31/2020, in the amount of $1,529,303.	$1,529,303	Jul 26, 2019
Other Administrative Action P00002	$0	Apr 19, 2019
Other Administrative Action P00001 · To revise article B.3. Advance understandings, paragraph B., subcontract.	$0	Dec 31, 2018
Original award	$1,519,121	Aug 30, 2018

Show all 22

About this award

Written by GovTribe AI · Mar 23, 2024

This is a cost-plus-fixed-fee contract awarded by the Department of Health and Human Services' National Institute of Allergy and Infectious Diseases to RxBio, Inc., a for-profit organization, for the IND-enabling development of RX100 as a medical countermeasure for gastrointestinal acute radiation syndrome. The contract has a potential value of $4,591,511.92 and a completion date of October 31, 2022. The contract was not set aside for any specific business type.

Quick answers

Who was awarded contract 75N93018C00052?

75N93018C00052 was awarded to Rxbio, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 1, 2018.

How much is contract 75N93018C00052 worth?

The government has obligated $4,591,512 on 75N93018C00052.

Was contract 75N93018C00052 competed?

The extent of competition for 75N93018C00052 was full and open competition. The government received 12 offers.

On GovTribe

See this award's full record

Every transaction and funding action
The awardee's other awards and teaming partners
Similar awards and recompete opportunities
Ask GovTribe AI about this award

Try for free Login